These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 3124067

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The in-vitro activity of ceftazidime against clinically important pathogens.
    Knothe H, Dette GA.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():33-41. PubMed ID: 19810167
    [Abstract] [Full Text] [Related]

  • 23. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
    Thabaut A, Meyran M, Huerre M.
    Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.
    Jorgensen JH, Crawford SA, Alexander GA.
    Antimicrob Agents Chemother; 1980 Jun; 17(6):937-42. PubMed ID: 6250470
    [Abstract] [Full Text] [Related]

  • 26. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.
    Neu HC, Labthavikul P.
    Antimicrob Agents Chemother; 1982 Jan; 21(1):11-8. PubMed ID: 6805421
    [Abstract] [Full Text] [Related]

  • 27. Comparative in vitro antimicrobial activity of carumonam, a new monocyclic beta-lactam.
    Smith BR, LeFrock JL, McCloskey RV, Donato JB, Weber SJ, Joseph WS.
    Antimicrob Agents Chemother; 1986 Feb; 29(2):346-9. PubMed ID: 3087280
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R, Gutmann L, Kitzis MD, Goldstein F, Acar JF.
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I, Warren C, Shannon K, King A, Hanslo D.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [Abstract] [Full Text] [Related]

  • 34. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
    Braveny I, Machka K, Elsser R.
    Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
    [Abstract] [Full Text] [Related]

  • 35. Antimicrobial resistance of Gram-negative bacilli isolates from inpatients and outpatients at Yaounde Central Hospital, Cameroon.
    Piéboji JG, Koulla-Shiro S, Ngassam P, Adiogo D, Njine T, Ndumbe P.
    Int J Infect Dis; 2004 May; 8(3):147-54. PubMed ID: 15109589
    [Abstract] [Full Text] [Related]

  • 36. Susceptibilities of gentamicin-resistant Gram-negative aerobic bacilli to cefotetan and other beta-lactams.
    Hart CA, Percival A.
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():95-101. PubMed ID: 6573329
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. In vitro activity of a new cephalosporin ME-1206 compared with other agents.
    Chin NX, Zhang YX, Neu HC.
    Diagn Microbiol Infect Dis; 1991 Jan; 14(5):417-24. PubMed ID: 1797456
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.